Opinion|Videos|October 23, 2025
Overcoming Resistance Mechanisms and Addressing Unmet Needs
Panelists discuss how overcoming resistance to EGFR TKIs requires next-generation inhibitors and more individualized treatment strategies.
Advertisement
Episodes in this series
Panelists discuss how resistance to EGFR tyrosine kinase inhibitors remains a key barrier to long-term disease control in non–small cell lung cancer.
They review common resistance mechanisms, such as secondary mutations (T790M, C797S), pathway activation, and histologic transformation, emphasizing how tumor heterogeneity complicates durable response.
The conversation highlights the importance of developing next-generation inhibitors, combination regimens, and central nervous system–penetrant agents. Panelists also address unmet needs, including improved testing, sequencing strategies, and access to emerging agents to ensure sustained clinical benefit and better outcomes across patient populations.
Advertisement
Related to this article
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
The analysis found a nonlinear association between systemic inflammation and overactive bladder, with stronger links at higher inflammation levels.
A real-world study found that adding a GLP-1 to SGLT2 inhibitor therapy was associated with lower kidney, cardiovascular, and mortality risks in CKD.
In experiments at MD Anderson, rising CD70 helps mantle cell lymphoma evade immunity; a CD70×CD3 bispecific restores T-cell killing and prolongs survival in resistant models.
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
2
Access and Innovation in North Carolina’s Research Triangle
3
Biomarker-Driven Care Is Racing Ahead of the Systems Built to Support It
4
An Odyssey of Symptoms, Setbacks, Treatments, and a Cure With CAR T-Cell Therapy
5